Yahoo Web Search

Sign In

Search results

  1. People also ask

  2. www.atalantatx.com › atalanta-therapeuticsAtalanta Therapeutics Launches With $110 Million to Pioneer ...

    Jan 11, 2021 · BOSTON, Mass. – Jan. 11, 2021 – Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, launched today with a Series A financing exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group.

    • Join Us

      At Atalanta, we offer a comprehensive array of benefits to...

    • Who We Are

      Dr. Sandrock spent 23 years at Biogen where he served in...

  3. cen.acs.org › pharmaceuticals › neuroscienceAtalanta Therapeutics launches to develop RNAi therapies for ...

    Jan 14, 2021 · Atalanta Therapeutics has launched with big plans to develop RNA interference (RNAi) therapies that will silence the expression of genes implicated in neurodegenerative diseases. The new company has $110 million in series A financing and partnerships with Biogen and Genentech.

  4. www.spglobal.com › marketintelligence › enAtalanta partners with Biogen, Genentech to develop therapies ...

    Jan 12, 2021 · Atalanta Therapeutics is partnering with Biogen Inc. and Genentech Inc., a unit of Roche Holding AG, to develop gene-based therapies for brain diseases. Under the partnership, the newly launched Atalanta will use its proprietary technology, called branched siRNA, to develop therapies for several neurodegenerative diseases, including Huntington ...

  5. pharmaphorum.com › news › rnai-biotech-atalantaRNAi biotech Atalanta debuts with $110m plus Biogen and Roche ...

    Jan 12, 2021 · US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological...

  6. www.nasdaq.com › press-release › atalantaAtalanta Therapeutics Launches With $110 Million to ... - Nasdaq

    Jan 11, 2021 · BOSTON -- (BUSINESS WIRE)-- Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, launched today with a Series A financing exclusively by...

  7. www.nature.com › articles › s41587/021/00838-2Atalanta pioneers siRNA for neurodegenerative diseases - Nature

    Feb 9, 2021 · With Biogen, Atalanta will develop RNAi therapeutics targeting the huntingtin ( HTT) gene, whose mutation causes Huntington’s disease, as well as additional unnamed CNS...

  8. www.biospace.com › article › rnai-focused-atalantaRNAi-Focused Atalanta Therapeutics Launches to ... - BioSpace

    Jan 11, 2021 · The Biogen deal will see Atalanta develop RNAi therapeutics for multiple targets, including HTT for the treatment of Huntington’s disease, as well as additional unnamed CNS targets. Atalanta will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products.

  1. Searches related to What is Atalanta doing with Biogen?

    what is atalanta doing with biogen and fdawhat is atalanta doing with biogen drug
    what is atalanta doing with biogen researchwhat is atalanta doing with biogen stock
    what is atalanta doing with biogen foodwhat is atalanta doing with biogen gas
    what is atalanta doing with biogen cancerwhat is atalanta doing with biogen benefits
  2. People also search for